A recent study involving 200 children with epileptic encephalopathy – epilepsy combined with intellectual or overall developmental disability – could lead to the development of a more rational anti-epileptic treatment strategy.
Approximately 30 per cent of patients with epilepsy do not respond to anti-epileptic drugs. In these cases, all neurologists can do is attempt to find the right combination of medication through trial and error.
A treatment that could target the root cause of epilepsy is a beacon of hope for these patients. But identifying the cause of the pathology is no easy feat.
“There are many genes involved. Each child can have different genetic mutations. Often the clinical symptoms do not clearly reflect the cause of epilepsy, which makes choosing the right treatment more difficult,”
said Jacques Michaud, pediatrician at CHU Sainte-Justine and Professor of Pediatrics and Neuroscience at the Faculty of Medicine of Université de Montreal.
The extensive research project was led by Michaud and his colleagues, Elsa Rossignol and Patrick Cossette of Universite de Montréal and Berge Minassian of the University of Toronto. The team identified eight new genes involved in this type of epilepsy thanks to their use of whole-genome sequencing, which had never been done before in an epileptic study of this scope.
“By learning about the pathophysiology of the genes involved, we hope to move towards a more appropriate treatment and decrease the amount of time spent on cumbersome medical assessments,”
The discovery has further-reaching implications. The findings not only validate the systematic approach to whole-genome sequencing in clinics, they also demonstrate that de novo mutations, otherwise known as spontaneous mutations not inherited by parents, are the main cause of this severe type of epilepsy.
“We were able to identify the specific genetic change that led to epileptic encephalopathy in 32 per cent of our subjects, which is quite remarkable. These children underwent extensive medical assessments, but no one could find the main cause. If we had conducted this analysis earlier, before all the medical tests were performed, it is possible the yield would have been even greater,”
Michaud, who holds the Jeanne and Jean-Louis Lévesque Research Chair on the genetic basis of brain diseases and the Jonathan Bouchard Research Chair on intellectual disability, believes that using whole-genome sequencing in a clinical setting has added value compared to the more conventional approach based on the exome, which represents less than 2 per cent of the genome.
“Thanks to whole-genome sequencing, we were able to identify a larger number of mutations,” he said. “In the future, the development of new methods for analyzing whole-genome sequencing data will make it possible to improve diagnostic performance.”
This scientific breakthrough was made possible thanks to the collective efforts of more than 100 researchers from around the world.
“We developed a network of collaborators in the United Kingdom, in several other European countries and in Australia to identify 30 other children with mutations in the same genes,” said Michaud. “This is how we were able to validate our findings.”
In the context of epilepsy, he added, de novo mutations seem to involve mechanisms of gene disruption that are unlike those involved in intellectual disability;
“Mutations in epilepsy tend to affect specific areas of the gene, whereas mutations associated with intellectual disability are more often distributed throughout the entire gene. This pattern suggests that mutations in epilepsy impart specific properties to their corresponding proteins, which may then manifest as a decrease or increase in protein activity. In intellectual disability, mutations will simply deactivate the gene.”
Knowledge of these mechanisms of action is crucial for the development of personalized epilepsy treatments. However, much more work is needed before these treatments can be harmonized with patients’ genetic profiles.